Usage Examples
- Switzerland is outside the EU procedures, so Swissmedic needs its own submission.
- The Swissmedic inspection covered the same site as the EU GMP inspection last year.
- Swissmedic authorisation does not follow automatically from an EMA opinion.
What is Swissmedic?
Swissmedic is the Swiss Agency for Therapeutic Products, the federal public law institution that authorises and supervises medicines and medical devices in Switzerland under the Therapeutic Products Act.
Swissmedic exists because Switzerland regulates its own therapeutic products market. Switzerland is not an EU or EEA member, so the EU's centralised and decentralised procedures do not reach it. A product lawfully marketed across the EU has no Swiss authorisation by virtue of that fact, and a separate decision by Swissmedic is required.
Swissmedic covers human medicines, veterinary medicines, complementary and herbal medicines, and medical devices placed on the Swiss market. Its functions span the lifecycle: authorising clinical trials, issuing manufacturing licences, authorising medicinal products, market surveillance, and inspecting companies. Swissmedic is not a government department in the ordinary sense; it is an autonomous federal public law institution attached to the Federal Department of Home Affairs, with its own budget and largely fee-financed.
Swissmedic in practice matters to sponsors as a distinct regulatory track that must be planned alongside FDA and EMA rather than assumed to follow from either. It participates in the Access Consortium, a coalition of medium-sized regulatory authorities, which shapes how work-sharing reviews can be used.
Not to be confused with
- EMA
- the EMA coordinates scientific evaluation for the EU and EEA. Switzerland is in neither, so an EMA opinion and Commission decision confer nothing in Switzerland. The two authorisations are independent decisions on independent submissions.
- Swiss cantonal authorities
- cantons handle certain enforcement and retail-level supervision within Switzerland. Swissmedic holds the federal authorisation and market-surveillance mandate for therapeutic products.
- A notified body
- for medical devices in Europe, conformity assessment is performed by notified bodies. Swissmedic is a national competent authority exercising public authority, not a commercial conformity assessment organisation.
- The Access Consortium
- the Consortium is a work-sharing coalition Swissmedic participates in, not a regulator. It can shape the review route; it does not issue authorisations.
Swissmedic's own remit defines what a sponsor must obtain in Switzerland.
What you must do
- 1Obtain Swiss authorisation for the therapeutic product from Swissmedic, which is the authority responsible for the authorisation and supervision of therapeutic productsSwissmedic - mandate
- 2Conduct activities under the Swiss legal framework for therapeutic products rather than relying on an EU authorisation, since Swissmedic's activities are based on the Therapeutic Products ActTherapeutic Products Act (TPA)
- 3Expect authorisation, licensing, surveillance, and inspection to sit with the same autonomous federal institution, which holds its own budget and organisational independenceSwissmedic - legal status
- 4Where a work-sharing route is intended, confirm eligibility through the Access Consortium rather than assuming bilateral recognitionAccess Consortium membership
Common mistakes
Assuming EU approval carries into Switzerland
Switzerland's non-membership of the EU and EEA means no automatic extension of a centralised authorisation. Programmes that treat Switzerland as an EU rounding error discover the gap at launch planning, when there is no Swiss authorisation to reference.
Planning Swiss timelines off the EU submission
Swissmedic runs its own procedures and its own clock. Building a Swiss launch date backwards from a CHMP opinion assumes a dependency that does not exist and leaves the Swiss dossier under-resourced.
Treating Swissmedic as covering only medicines
its remit expressly includes medical devices alongside human, veterinary, and complementary medicines. Device teams that map Switzerland only to a European notified body route miss the national competent authority entirely.
When This Matters
- Switzerland is outside the EU procedures, so Swissmedic needs its own submission.
- The Swissmedic inspection covered the same site as the EU GMP inspection last year.
- Swissmedic authorisation does not follow automatically from an EMA opinion.
Frequently Asked Questions
No. Switzerland is not an EU or EEA member, so a centralised EMA authorisation does not extend to it. Swissmedic authorises therapeutic products for the Swiss market under the Therapeutic Products Act, which means a separate submission and a separate authorisation decision.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
- Regulatory Intelligence
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
- Medical Device Solutions
510(k), De Novo, and PMA workflows from predicate analysis to filing.
- Lifecycle Management
Track every sequence operation, amendment, and supplement across the product lifecycle.
